We are live on ! Find out more

Telix Pharmaceuticals

TLX

Market cap $3.27B

9.63 USD

+0.21

2.23%

At close Updated Nov 6, 4:00 PM EST

1 day

2.23%

5 days

5.02%

1 month

-10.67%

3 months

-9.49%

6 months

-13.32%

Year to date

26.38%

1 year

-2.53%

5 years

-36.44%

10 years

-36.44%

About: Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.

Employees: 1,184

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 29.6%

Neutral 66.7%

Negative 3.7%

Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth

Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year remains at 70% or higher New Cook Medical agreement positions TULSA-PRO ® within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach across the United States Richard Fabian appointed as CEO, effective January 14, 2027; Arun Menawat to transition to Executive Chairman; Matthew Sobczyk becomes permanent CFO; Jason Mills joins Board TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the third quarter ended September 30, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).

Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth

Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push

Telix Pharmaceuticals NASDAQ: TLX outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management emphasizing supply-chain control, therapeutic expansion and a target to transition toward earnings growth beginning in 2028.

Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Telix Pharmaceuticals maintains a buy rating, driven by robust 3Q26 performance and the strategic ITM acquisition to diversify revenue and strengthen isotope supply. 3Q26 revenue rose 19% YoY to $245 million, with Precision Medicine up 30% YoY; Pixclara approval and pipeline advancements offer additional growth catalysts. The ITM acquisition, valued at $1.65 billion with up to $700 million in contingent payments, is expected to deliver $50 million in synergies and meaningful EBITDA from 2027.

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Telix Reports Third Quarter 2026 Financial Performance

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).

Telix Reports Third Quarter 2026 Financial Performance

Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix

The joint venture between IBA and Framatome will leverage Telix's capabilities to accelerate the production and availability of Astatine-211 in the US market.

Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy.

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides Profound with increased access to urologists via a strong strategic partner and creates a framework to further advance clinical evidence-based patient selection and optimization of patient treatment plans TORONTO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is pleased to announce entering into a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX) (“Telix”), a commercial-stage global radiopharmaceutical company. The agreement establishes a framework through which the companies intend to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's advanced prostate-specific membrane antigen (“PSMA”) targeting PET molecular imaging technologies, Gozellix® and Illuccix® 1, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO® platform across the prostate care continuum.

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U.S.) have been dosed with Pixclara® (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron emission tomography (PET) drug for glioma (brain cancer) imaging.

First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®

IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics

IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®

Zacks Investment Research

Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade

See News Rankings

Price charts implemented using Lightweight Charts™